W Michael Hooten1, Jennifer L St Sauver2, Michaela E McGree3, Debra J Jacobson3, David O Warner4. 1. Department of Anesthesiology, Mayo Clinic, Rochester, MN. Electronic address: hooten.william@mayo.edu. 2. Division of Epidemiology, Department of Health Sciences Research, the Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN. 3. Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, the Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN. 4. Department of Anesthesiology, Mayo Clinic, Rochester, MN.
Abstract
OBJECTIVES: To determine what proportion of a geographically defined population who receive new opioid prescriptions progresses to episodic or long-term patterns of opioid prescribing and to explore the clinical characteristics associated with patterns of opioid prescribing. PATIENTS AND METHODS: Population-based drug prescription records for the population of Olmsted County between January 1 and December 31, 2009, were obtained using the Rochester Epidemiology Project medical records linkage system (N=142,377). All medical records were reviewed for a random sample of 293 patients who had a new ("incident") prescription for an opioid analgesic in 2009. Patients were followed through their medical records for 1 year after their initial prescription date, with patterns of opioid prescribing categorized as short-term, episodic, or long-term. RESULTS: Overall, 293 patients received 515 new opioid prescriptions in 2009. Of these, 61 (21%) progressed to an episodic prescribing pattern and 19 (6%) progressed to a long-term prescribing pattern. In multivariable logistic regression analyses, substance abuse was significantly associated (P<.001) with a long-term opioid prescribing pattern as compared with an short-term opioid prescribing pattern. Past or current nicotine use (P=.03) and substance abuse (P=.04) were significantly associated with an episodic or long-term prescribing pattern as compared with a short-term prescribing pattern. CONCLUSION: Knowledge of the clinical characteristics associated with the progression of a short-term to an episodic or long-term opioid prescribing pattern could aid in the identification of at-risk patients and provide the basis for developing targeted clinical interventions.
OBJECTIVES: To determine what proportion of a geographically defined population who receive new opioid prescriptions progresses to episodic or long-term patterns of opioid prescribing and to explore the clinical characteristics associated with patterns of opioid prescribing. PATIENTS AND METHODS: Population-based drug prescription records for the population of Olmsted County between January 1 and December 31, 2009, were obtained using the Rochester Epidemiology Project medical records linkage system (N=142,377). All medical records were reviewed for a random sample of 293 patients who had a new ("incident") prescription for an opioid analgesic in 2009. Patients were followed through their medical records for 1 year after their initial prescription date, with patterns of opioid prescribing categorized as short-term, episodic, or long-term. RESULTS: Overall, 293 patients received 515 new opioid prescriptions in 2009. Of these, 61 (21%) progressed to an episodic prescribing pattern and 19 (6%) progressed to a long-term prescribing pattern. In multivariable logistic regression analyses, substance abuse was significantly associated (P<.001) with a long-term opioid prescribing pattern as compared with an short-term opioid prescribing pattern. Past or current nicotine use (P=.03) and substance abuse (P=.04) were significantly associated with an episodic or long-term prescribing pattern as compared with a short-term prescribing pattern. CONCLUSION: Knowledge of the clinical characteristics associated with the progression of a short-term to an episodic or long-term opioid prescribing pattern could aid in the identification of at-risk patients and provide the basis for developing targeted clinical interventions.
Authors: Jennifer L St Sauver; Brandon R Grossardt; Cynthia L Leibson; Barbara P Yawn; L Joseph Melton; Walter A Rocca Journal: Mayo Clin Proc Date: 2012-02 Impact factor: 7.616
Authors: Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Joshua J Pankratz; Scott M Brue; Walter A Rocca Journal: Int J Epidemiol Date: 2012-11-18 Impact factor: 7.196
Authors: Wenjun Zhong; Hilal Maradit-Kremers; Jennifer L St Sauver; Barbara P Yawn; Jon O Ebbert; Véronique L Roger; Debra J Jacobson; Michaela E McGree; Scott M Brue; Walter A Rocca Journal: Mayo Clin Proc Date: 2013-06-19 Impact factor: 7.616
Authors: Hilary J Mosher; Lan Jiang; Mary S Vaughan Sarrazin; Peter Cram; Peter J Kaboli; Mark W Vander Weg Journal: J Hosp Med Date: 2013-12-06 Impact factor: 2.960
Authors: A Vania Apkarian; Volker Neugebauer; George Koob; Scott Edwards; Jon D Levine; Luiz Ferrari; Mark Egli; Soundar Regunathan Journal: Pharmacol Biochem Behav Date: 2013-10-02 Impact factor: 3.533
Authors: Walter A Rocca; Barbara P Yawn; Jennifer L St Sauver; Brandon R Grossardt; L Joseph Melton Journal: Mayo Clin Proc Date: 2012-11-28 Impact factor: 7.616
Authors: Zachary F Meisel; Nicoleta Lupulescu-Mann; Christina J Charlesworth; Hyunjee Kim; Benjamin C Sun Journal: Ann Emerg Med Date: 2019-06-20 Impact factor: 5.721
Authors: Joseph A Gil; Vidhya Gunaseelan; Steven F DeFroda; Chad M Brummett; Asheesh Bedi; Jennifer F Waljee Journal: Am J Sports Med Date: 2019-02-08 Impact factor: 6.202
Authors: Richard A Deyo; Sara E Hallvik; Christi Hildebran; Miguel Marino; Eve Dexter; Jessica M Irvine; Nicole O'Kane; Joshua Van Otterloo; Dagan A Wright; Gillian Leichtling; Lisa M Millet Journal: J Gen Intern Med Date: 2016-08-02 Impact factor: 5.128
Authors: Christopher L Wu; Adam B King; Timothy M Geiger; Michael C Grant; Michael P W Grocott; Ruchir Gupta; Jennifer M Hah; Timothy E Miller; Andrew D Shaw; Tong J Gan; Julie K M Thacker; Michael G Mythen; Matthew D McEvoy Journal: Anesth Analg Date: 2019-08 Impact factor: 5.108
Authors: Jorge A Zamora-Legoff; Sara J Achenbach; Cynthia S Crowson; Megan L Krause; John M Davis; Eric L Matteson Journal: Clin Rheumatol Date: 2016-03-29 Impact factor: 2.980